Copyright
©The Author(s) 2024.
World J Nephrol. Jun 25, 2024; 13(2): 92498
Published online Jun 25, 2024. doi: 10.5527/wjn.v13.i2.92498
Published online Jun 25, 2024. doi: 10.5527/wjn.v13.i2.92498
Variable | All patients | Survivors | Non-survivors | P value |
Age in years | 59.7 ± 17.1 | 58.6 ± 16.0 | 79.0 ± 9.0 | 0.000 |
Male sex | 99 (60.0) | 84 (59.0) | 15 (65.0) | 0.650 |
T2DM | 55 (33.4) | 43 (30.0) | 12 (50.0) | 0.050 |
Hypertension | 87 (53.0) | 70 (49.0) | 17 (74.0) | 0.040 |
COPD or asthma | 23 (14.0) | 17 (12.0) | 6 (26.0) | 0.100 |
SOFA score | 2 (1.0-3.0) | 2 (1.0-3.0) | 3 (1.5-4.0) | 0.110 |
Charlson’s score | 3 (1.0-4.0) | 2 (1.0-4.0) | 5 (4.0-7.0) | 0.000 |
SAPS 3 | 42.0 ± 19.0 | 42.0 ± 16.4 | 61.0 ± 15.0 | 0.000 |
Antimicrobial treatment | 89 (54.0) | 66 (46.8) | 23 (100) | 0.000 |
PO2/FIO2 | 296 ± 87 | 308 ± 94 | 264 ± 116 | 0.360 |
HFO2/NIV | 83 (50.6) | 67 (47.5) | 16 (69.5) | 0.040 |
Lung involvement | 0.360 | |||
< 25% | 13.4 | 12.0 | 21.7 | |
25%-50% | 44.5 | 46.8 | 30.4 | |
50%-75% | 34.7 | 34.7 | 34.7 | |
> 75% | 6.7 | 5.6 | 13.0 | |
VAD at admission | 25 (15.0) | 18 (12.0) | 7 (30.0) | 0.050 |
VAD any time | 60 (37.0) | 39 (27.0) | 21 (91.0) | 0.000 |
MV | 65 (40.0) | 43 (30.0) | 22 (95.0) | 0.000 |
AKI | 50 (30.4) | 28 (19.8) | 22 (95.6) | 0.000 |
KDIGO 1 | 18 (11.0) | 17 (12.0) | 1 (4.3) | 0.000 |
KDIGO 2 | 7 (4.2) | 5 (3.5) | 2 (8.7) | |
KDIGO 3 | 25 (15.2) | 6 (4.2) | 19 (82.6) | |
Dialysis | 19 (11.6) | 2 (1.4) | 17 (73.0) | 0.000 |
Hospital stay in day | 13 (10.0-21.0) | 17 (9.0-20.5) | 22 (13.0-32.0) | 0.005 |
ICU stay in day | 12.6 (5-17) | 11.0 (9-14) | 21.0 (18-25) | 0.000 |
Illness day | 7.0 (5.0-9.0) | 10.1 (5.0-8.7) | 8.2 (3.0-17.0) | 0.003 |
Days in hospital | 0 (0-1) | 0 (0-1) | 0 (0-1) | 0.410 |
Ferritin (normal range: 12 ng/mL-300 ng/mL) | 985 ± 1447 | 1088 ± 1529 | 679 ± 609 | 0.170 |
Leukocyte count (normal range: 3.6 × 109/L-11.0 × 109/L) | 7.0 (5.5-9.1) | 7.1 (5.1-9.4) | 6.6 (4.3-8.9) | 0.720 |
Lymphocyte count (normal range: 1 × 109/L-4 × 109/L) | 0.86 | 0.92 | 0.78 | 0.040 |
Platelet count (normal range: 150 × 109/L-400 × 109/L) | 179 (151-237) | 191 (151-244) | 169 (148-219) | 0.290 |
Creatinine (normal range: 0.5 mg/dL-1.3 mg/dL) | 0.83 (0.67-0.98) | 0.83 (0.65-0.98) | 0.84 (0.69-0.99) | 0.770 |
D dimer (normal range < 250 ng/mL) | 832 (563-1740) | 880 (536-1651) | 1512 (746-2151) | 0.040 |
Fibrinogen (normal range: 200 mg/dL-400 mg/dL) | 532 ± 185 | 555 ± 206 | 580 ± 179 | 0.580 |
Total bilirubin (normal range: 0.2 mg/dL-1.2 mg/dL) | 0.5 (0.4-0.7) | 0.5 (0.4-0.7) | 0.6 (0.4-0.7) | 0.930 |
Parameter | All patients | Survivors | Non-survivors | P value |
PH (normal range: 7.38-7.42) | 7.46 (7.42-7.53) | 7.45 (7.40-7.47) | 7.45 (7.40-7.50) | 0.850 |
PCO2 (normal range: 36 mmHg-44 mmHg) | 34.1 ± 5.6 | 34.0 ± 5.7 | 34.5 ± 4.8 | 0.660 |
Bicarbonate (normal range: 24 mEq/L ± 2 mEq/L) | 23.3 (21.0-24.8) | 23.3 (20.9-24.9) | 23.1 (21.7-24.4) | 0.630 |
Lactate normal range: (4 mg/dL-18 mg/dL) | 12.1 (2.0-15.9) | 11.5 (1.9-15.2) | 13.9 (10.7-21.2) | 0.130 |
Albumin (normal range: 4.0 g/dL-5.5 g/dL) | 3.6 (3.2-3.8) | 3.6 (3.3-3.8) | 3.4 (3.2-3.8) | 0.650 |
Phosphorus (normal range: 2.5 mg/dL–4.5 mg/dL) | 3.57 ± 0.84 | 3.58 ± 0.86 | 3.44 ± 0.68 | 0.450 |
Sodium (normal range: 135 mEq/L-142 mEq/L) | 135 (133-138) | 136 (134-138) | 135 (129-136) | 0.010 |
Potassium (normal range: 3.5 mEq/L-5.2 mEq/L) | 4.17 ± 0.51 | 4.17 ± 0.51 | 4.15 ± 0.52 | 0.820 |
Chloride (normal range: 96 mEq/L-106 mEq/L) | 100 (97-103) | 100 (98-103) | 98 (94-100) | 0.030 |
SIDa | 37.96 ± 4.30 | 37.81 ± 4.33 | 37.86 ± 4.21 | 0.920 |
SIDe | 35.35 ± 3.50 | 35.42 ± 3.64 | 34.94 ± 3.15 | 0.670 |
SIG | 2.69 (-0.30 to 4.94) | 2.67 (0.21-4.99) | 2.71 (-0.40 to 4.88) | 0.930 |
SBE | -0.35 (-2.90 to 1.30) | -0.33 (-3.00 to 1.40) | -0.84 (-2.30 to 0.28) | 0.740 |
Chloride effect | -2.44 (-4.80 to 0.28) | -2.44 (-5.50 to 0.70) | -2.58 (-4.80 to 11.58) | 0.580 |
Lactate effect | -1.47 (-1.90 to 1.20) | -1.45 (-1.86 to 1.20) | -1.69 (-2.34 to 1.30) | 0.240 |
Albumin effect | 1.51 (0.60-2.60) | 1.49 (0.60-2.46) | 1.82 (0.76-2.73) | 0.730 |
Phosphorus effect | -0.02 ± 0.50 | 0 ± 0.52 | 0.10 ± 0.40 | 0.270 |
- Citation: de Souza SP, Caldas JR, Lopes MB, Duarte Silveira MA, Coelho FO, Oliveira Queiroz I, Domingues Cury P, Passos RDH. Physico-chemical characterization of acid base disorders in patients with COVID-19: A cohort study. World J Nephrol 2024; 13(2): 92498
- URL: https://www.wjgnet.com/2220-6124/full/v13/i2/92498.htm
- DOI: https://dx.doi.org/10.5527/wjn.v13.i2.92498